skip to main content

DOE PAGESDOE PAGES

Title: Bulk production and evaluation of high specific activity 186g Re for cancer therapy using enriched 186 WO 3 targets in a proton beam

Rhenium-186 g (t 1/2 = 3.72 d) is a β– emitting isotope suitable for theranostic applications. Current production methods rely on reactor production by way of the reaction 185Re(n,γ) 186gRe, which results in low specific activities limiting its use for cancer therapy. Production via charged particle activation of enriched 186W results in a 186gRe product with a much specific activity, allowing it to be used more broadly for targeted radiotherapy applications. Furthermore, this targets the unmet clinical need for more efficient radiotherapeutics.
Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Report Number(s):
LA-UR-16-29352
Journal ID: ISSN 0969-8051; TRN: US1700520
Grant/Contract Number:
AC52-06NA25396
Type:
Accepted Manuscript
Journal Name:
Nuclear Medicine and Biology
Additional Journal Information:
Journal Volume: 49; Journal Issue: C; Journal ID: ISSN 0969-8051
Publisher:
Elsevier
Research Org:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Sponsoring Org:
USDOE Office of Science (SC), Nuclear Physics (NP) (SC-26)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; Inorganic and Physical Chemistry
OSTI Identifier:
1345946
Alternate Identifier(s):
OSTI ID: 1415249

Mastren, Tara, Radchenko, Valery, Bach, Hong T., Balkin, Ethan R., Birnbaum, Eva R., Brugh, Mark, Engle, Jonathan W., Gott, Matthew D., Guthrie, James, Hennkens, Heather M., John, Kevin D., Ketring, Alan R., Kuchuk, Marina, Maassen, Joel R., Naranjo, Cleo M., Nortier, F. Meiring, Phelps, Tim E., Jurisson, Silvia S., Wilbur, D. Scott, and Fassbender, Michael E.. Bulk production and evaluation of high specific activity 186g Re for cancer therapy using enriched 186 WO 3 targets in a proton beam. United States: N. p., Web. doi:10.1016/j.nucmedbio.2017.02.006.
Mastren, Tara, Radchenko, Valery, Bach, Hong T., Balkin, Ethan R., Birnbaum, Eva R., Brugh, Mark, Engle, Jonathan W., Gott, Matthew D., Guthrie, James, Hennkens, Heather M., John, Kevin D., Ketring, Alan R., Kuchuk, Marina, Maassen, Joel R., Naranjo, Cleo M., Nortier, F. Meiring, Phelps, Tim E., Jurisson, Silvia S., Wilbur, D. Scott, & Fassbender, Michael E.. Bulk production and evaluation of high specific activity 186g Re for cancer therapy using enriched 186 WO 3 targets in a proton beam. United States. doi:10.1016/j.nucmedbio.2017.02.006.
Mastren, Tara, Radchenko, Valery, Bach, Hong T., Balkin, Ethan R., Birnbaum, Eva R., Brugh, Mark, Engle, Jonathan W., Gott, Matthew D., Guthrie, James, Hennkens, Heather M., John, Kevin D., Ketring, Alan R., Kuchuk, Marina, Maassen, Joel R., Naranjo, Cleo M., Nortier, F. Meiring, Phelps, Tim E., Jurisson, Silvia S., Wilbur, D. Scott, and Fassbender, Michael E.. 2017. "Bulk production and evaluation of high specific activity 186g Re for cancer therapy using enriched 186 WO 3 targets in a proton beam". United States. doi:10.1016/j.nucmedbio.2017.02.006. https://www.osti.gov/servlets/purl/1345946.
@article{osti_1345946,
title = {Bulk production and evaluation of high specific activity 186g Re for cancer therapy using enriched 186 WO 3 targets in a proton beam},
author = {Mastren, Tara and Radchenko, Valery and Bach, Hong T. and Balkin, Ethan R. and Birnbaum, Eva R. and Brugh, Mark and Engle, Jonathan W. and Gott, Matthew D. and Guthrie, James and Hennkens, Heather M. and John, Kevin D. and Ketring, Alan R. and Kuchuk, Marina and Maassen, Joel R. and Naranjo, Cleo M. and Nortier, F. Meiring and Phelps, Tim E. and Jurisson, Silvia S. and Wilbur, D. Scott and Fassbender, Michael E.},
abstractNote = {Rhenium-186 g (t1/2 = 3.72 d) is a β– emitting isotope suitable for theranostic applications. Current production methods rely on reactor production by way of the reaction 185Re(n,γ)186gRe, which results in low specific activities limiting its use for cancer therapy. Production via charged particle activation of enriched 186W results in a 186gRe product with a much specific activity, allowing it to be used more broadly for targeted radiotherapy applications. Furthermore, this targets the unmet clinical need for more efficient radiotherapeutics.},
doi = {10.1016/j.nucmedbio.2017.02.006},
journal = {Nuclear Medicine and Biology},
number = C,
volume = 49,
place = {United States},
year = {2017},
month = {6}
}